PDF(Pubmed)
Abstract：
UNASSIGNED: Despite U.S. Preventive Services Task Force and American Cancer Society endorsement of primary HPV screening, limited published data shows low uptake.
UNASSIGNED: Assess cervical cancer screening rates over time, particularly primary HPV test uptake, among patients in a midwestern practice.
UNASSIGNED: Evaluate associations between sociodemographics and screening adherence.
UNASSIGNED: Cross-sectional study. Qualifying subjects and type of screening test used were identified by applying ICD-9, ICD-10, lab test, and CPT codes to the Unified Data Platform. Sociodemographics were found through the electronic health record.
UNASSIGNED: Primary HPV uptake represented <1% of annual screening from 1/2017 to 1/2022. On 1/1/2022, only 55% of 21 to 29 year old and 63% of 30 to 65 year old were up to date with screening among the studied population. For 21 to 29 year old, compared with White women, Black women were 28% less likely to be screened [RR = 0.72 (0.66-0.79)]. Compared with never-smokers, current smokers were 9% less likely to be screened [RR = 0.91 (0.87-0.96)], past smokers were 14% more likely [RR = 1.14 (1.09-1.2)]. Among 30 to 65 year old, compared with White women, Black women were 14% less likely to be screened [RR = 0.86 (0.81-0.9)]. Compared with never-smokers, current smokers were 21% less likely to be screened [RR = 0.79 (0.77-0.81)], past smokers were 6% less likely [RR = 0.94 (0.92-0.95)]. Jointly considering race, ethnicity, smoking status, Charlson score, and rurality, findings were similar for 21 to 29 year old; Black women were screened less than White women [RR = 0.73 (0.67-0.79)]; current smokers [RR = 0.9 (0.85-0.94)] and past smokers [RR = 1.12 (1.06-1.17)] were screened less than never smokers. For 30 to 65 year old, Black women were screened less than White women [RR = 0.83 (0.79-0.88)]; current smokers [RR = 0.8 (0.78-0.81)] and past smokers [RR = 0.95 (0.93-0.96)] were screened less than never smokers.
UNASSIGNED: Screening rates remained below the Healthy People 2030 goal of 79.2% over time, particularly for younger Black women and current smokers, with minimal use of primary HPV screening.
UNASSIGNED: Assess cervical cancer screening rates over time, particularly primary HPV test uptake, among patients in a midwestern practice.
UNASSIGNED: Evaluate associations between sociodemographics and screening adherence.
UNASSIGNED: Cross-sectional study. Qualifying subjects and type of screening test used were identified by applying ICD-9, ICD-10, lab test, and CPT codes to the Unified Data Platform. Sociodemographics were found through the electronic health record.
UNASSIGNED: Primary HPV uptake represented <1% of annual screening from 1/2017 to 1/2022. On 1/1/2022, only 55% of 21 to 29 year old and 63% of 30 to 65 year old were up to date with screening among the studied population. For 21 to 29 year old, compared with White women, Black women were 28% less likely to be screened [RR = 0.72 (0.66-0.79)]. Compared with never-smokers, current smokers were 9% less likely to be screened [RR = 0.91 (0.87-0.96)], past smokers were 14% more likely [RR = 1.14 (1.09-1.2)]. Among 30 to 65 year old, compared with White women, Black women were 14% less likely to be screened [RR = 0.86 (0.81-0.9)]. Compared with never-smokers, current smokers were 21% less likely to be screened [RR = 0.79 (0.77-0.81)], past smokers were 6% less likely [RR = 0.94 (0.92-0.95)]. Jointly considering race, ethnicity, smoking status, Charlson score, and rurality, findings were similar for 21 to 29 year old; Black women were screened less than White women [RR = 0.73 (0.67-0.79)]; current smokers [RR = 0.9 (0.85-0.94)] and past smokers [RR = 1.12 (1.06-1.17)] were screened less than never smokers. For 30 to 65 year old, Black women were screened less than White women [RR = 0.83 (0.79-0.88)]; current smokers [RR = 0.8 (0.78-0.81)] and past smokers [RR = 0.95 (0.93-0.96)] were screened less than never smokers.
UNASSIGNED: Screening rates remained below the Healthy People 2030 goal of 79.2% over time, particularly for younger Black women and current smokers, with minimal use of primary HPV screening.
摘要：
■尽管美国预防服务工作组和美国癌症协会认可HPV初筛，有限的公布数据显示低摄取。
■随时间评估宫颈癌筛查率，特别是原发性HPV测试摄取，在中西部诊所的患者中。
■评估社会人口统计学和筛查依从性之间的关联。
■横断面研究。通过应用ICD-9，ICD-10，实验室测试来确定所使用的合格受试者和筛选测试类型，和CPT代码到统一数据平台。社会人口统计数据是通过电子健康记录找到的。
■从2017年1月至2022年1月1日，原发性HPV摄取占年度筛查的<1％。在2022年1月1日，只有55％的21至29岁的人和63％的30至65岁的人在研究人群中进行了最新的筛查。对于21到29岁的人来说，与白人女性相比，黑人女性接受筛查的可能性降低了28％[RR=0.72（0.66-0.79）]。与从不吸烟者相比，目前吸烟者接受筛查的可能性低9%[RR=0.91(0.87-0.96)]，既往吸烟者的可能性增加14%[RR=1.14(1.09-1.2)].在30到65岁之间，与白人女性相比，黑人女性接受筛查的可能性降低了14%[RR=0.86(0.81-0.9)]。与从不吸烟者相比，目前吸烟者接受筛查的可能性降低了21%[RR=0.79(0.77-0.81)]，既往吸烟者的可能性降低6%[RR=0.94(0.92-0.95)].共同考虑种族，种族,吸烟状况,Charlson得分,和乡村，21~29岁的研究结果相似;黑人女性的筛查率低于白人女性[RR=0.73(0.67-0.79)];当前吸烟者[RR=0.9(0.85-0.94)]和过去吸烟者[RR=1.12(1.06-1.17)]的筛查率低于从未吸烟者.30到65岁，黑人女性的筛查率低于白人女性[RR=0.83（0.79-0.88）]；当前吸烟者[RR=0.8（0.78-0.81）]和过去吸烟者[RR=0.95（0.93-0.96）]的筛查率低于从未吸烟者。
■随着时间的推移，筛查率仍低于健康人群2030年79.2%的目标，特别是对于年轻的黑人女性和目前的吸烟者，尽量减少使用原发性HPV筛查。
■随时间评估宫颈癌筛查率，特别是原发性HPV测试摄取，在中西部诊所的患者中。
■评估社会人口统计学和筛查依从性之间的关联。
■横断面研究。通过应用ICD-9，ICD-10，实验室测试来确定所使用的合格受试者和筛选测试类型，和CPT代码到统一数据平台。社会人口统计数据是通过电子健康记录找到的。
■从2017年1月至2022年1月1日，原发性HPV摄取占年度筛查的<1％。在2022年1月1日，只有55％的21至29岁的人和63％的30至65岁的人在研究人群中进行了最新的筛查。对于21到29岁的人来说，与白人女性相比，黑人女性接受筛查的可能性降低了28％[RR=0.72（0.66-0.79）]。与从不吸烟者相比，目前吸烟者接受筛查的可能性低9%[RR=0.91(0.87-0.96)]，既往吸烟者的可能性增加14%[RR=1.14(1.09-1.2)].在30到65岁之间，与白人女性相比，黑人女性接受筛查的可能性降低了14%[RR=0.86(0.81-0.9)]。与从不吸烟者相比，目前吸烟者接受筛查的可能性降低了21%[RR=0.79(0.77-0.81)]，既往吸烟者的可能性降低6%[RR=0.94(0.92-0.95)].共同考虑种族，种族,吸烟状况,Charlson得分,和乡村，21~29岁的研究结果相似;黑人女性的筛查率低于白人女性[RR=0.73(0.67-0.79)];当前吸烟者[RR=0.9(0.85-0.94)]和过去吸烟者[RR=1.12(1.06-1.17)]的筛查率低于从未吸烟者.30到65岁，黑人女性的筛查率低于白人女性[RR=0.83（0.79-0.88）]；当前吸烟者[RR=0.8（0.78-0.81）]和过去吸烟者[RR=0.95（0.93-0.96）]的筛查率低于从未吸烟者。
■随着时间的推移，筛查率仍低于健康人群2030年79.2%的目标，特别是对于年轻的黑人女性和目前的吸烟者，尽量减少使用原发性HPV筛查。
